IDH-1R132H mutation status in diffuse glioma patients: implications for classification
PDF | HTML | How to cite
Metrics: PDF 1208 views | HTML 2362 views | ?
Peng-fei Wang1,*, Ning Liu1,*, Hong-wang Song1, Kun Yao2, Tao Jiang1,3,4,5,**, Shou-wei Li1,**, Chang-Xiang Yan1,**
1Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China
2Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijing, China
3Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
4Beijing Neurosurgical Institute, Beijing, China
5Beijing Institute for Brain Disorders, Beijing, China
*Peng-fei Wang and Ning Liu are the co-first authors
**Chang-Xiang Yan, Shou-wei Li and Tao Jiang are the co-corresponding authors
Chang-Xiang Yan, email: [email protected]
Keywords: gliomas, IDH-1R132H mutation, prognosis, molecular pathology, Ki-67
Received: December 12, 2015 Accepted: April 11, 2016 Published: April 22, 2016
WHO2007 grading of diffuse gliomas in adults is well-established. However, IDH mutations make classification of gliomas according to the WHO2007 edition controversial. Here, we characterized IDH-1R132H mut status in a cohort of 670 adult patients with different WHO2007 grades of diffuse glioma. Patient characteristics, clinical data and prognoses were obtained from medical records. Patients with IDH-1R132H mut were younger and had better clinical outcomes than those without mutations. Differences in age among patients with astrocytomas of different WHO2007 grades were eliminated after patients were grouped based on IDH-1R132H status. IDH-1R132H mut was present more often in patients with lower Ki-67 and MGMT protein levels and higher mutant p53 levels. Ki-67 was also strongly associated with WHO2007 grade independently of IDH-1R132H mut status. Moreover, patients with Ki-67<30 survived longer than those with Ki-67≥30, regardless of IDH-1R132H mut status. Patients in the IDH-1R132H mut group with lower MGMT protein levels also had better clinical outcomes than those in other groups. Our results indicate that to better treat gliomas, IDH mutation status should be included when determining WHO2007 grade in glioma patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.